Market News & Trends
Ascendia Pharmaceuticals Expanding Injectable Manufacturing Capabilities in 2024
Ascendia Pharmaceuticals is all set to unveil its new injectables manufacturing opportunities with the launch of a state-of-the-art sterile cGMP production facility in March 2024…..
AustinPx Partners With Microsize on KinetiSol Technology, Partnership Strengthens Commercialization Options for AustinPx’s Clients
AustinPx and Microsize recently announced the strategic partnership to accelerate the commercial application of AustinPx’s KinetiSol Technology platform. The collaboration will enable….
Kindeva Drug Delivery Launches New Analytical Services Global Business Unit
Kindeva Drug Delivery recently announced the expansion of its analytical services capabilities — launching a new global business unit offering integrated and stand-alone analytical support to…
BioNTech & DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate
BioNTech SE and Duality Biologics recently announced the US FDA granted Fast Track designation for BNT325/DB-1305 for the treatment of patients with platinum-resistant ovarian epithelial cancer….
Cristalia Products With Nemera’s Reusable Pen Injector Commercialized in Brazil
Cristalia’s human growth hormone will be administered with CRISPEN. Approved by ANVISA1, CRISPEN is part of Nemera’s state-of-the-art pen injector platform PENDURA AD……..
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
Iterum Therapeutics plc recently announced positive topline results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil…
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases With University of Florida
Vaxxinity, Inc. recently announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on…
Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved With Potential First-in-Class Oral Treatment for PKU
Jnana Therapeutics recently announced positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with phenylketonuria (PKU). JNT-517, a small molecule inhibitor…
Oxford Biomedica Completes Acquisition of ABL Europe
The acquisition of ABL Europe, a pure-play European CDMO, strengthens Oxford Biomedica’s position as a world-leading cell and gene therapy CDMO. This strategic move broadens….
Longeveron Receives Notice of US Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B
Longeveron Inc. recently announced it received a notice of patent allowance from the United States Patent and Trademark Office (PTO) for Medicinal Signaling Cells (MSCs),…
First Patient Dosed With LIXTE’s LB-100 & GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
LIXTE Biotechnology Holdings, Inc. recently announced the dosing of the first patient in a Phase 1b/2 clinical trial to assess whether adding LIXTE’s LB-100 to GSK’s…
GDMC Secures $21-Million Growth Capital Funding to Expand Global Genetic Medicines Design & Manufacturing Operations
Genetic Design and Manufacturing Corporation (GDMC) recently announced a Series A funding of $21 million. The funding round is led by Celadon Partners, an Asia…
Repare Therapeutics Announces Achievement of $40-Million Roche Clinical Milestone Payment
Milestone payment triggered by dosing of the first patient in camonsertib-based arm in Roche’s Phase 2 TAPISTRY platform clinical trial….
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients With Advanced Cancer Resulting in Recommended Phase 2 Doses
Processa Pharmaceuticals, Inc. recently announced the successful completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine (NGC-Cap). From the…
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients With Rheumatoid Arthritis
Incannex Healthcare Inc. recently announced patient dosing has commenced in the Phase 2 clinical trial assessing IHL-675A in patients with rheumatoid arthritis (RA). IHL-675A is…
Evaxion to Develop Tailored Novel Cancer Vaccines Based Upon a New Untapped Source of AI-Discovered Targets
Evaxion Biotech A/S recently announced an expanded commitment to developing tailored cancer vaccines by targeting a novel category of AI-identified tumor antigens, named Endogenous Retroviruses…
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
Silo Pharma, Inc. recently announced its Alzheimer’s disease therapeutic SPC-14 showed positive efficacy in small animals. Data from a study conducted at Columbia University in collaboration…
Recipharm, Medspray & Resyca Enter Exclusive License Agreement to Develop Nasally Delivered Drug Products Using Proprietary Soft Mist Technology
Recipharm recently announced an exclusive license and collaboration agreement with Medspray and Resyca to develop soft mist nasal delivery devices for single and combination drug products. This collaboration….
Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR
Ensysce Biosciences, Inc. recently announced receipt of notice from the US FDA that it has granted Breakthrough Therapy Designation (BTD) for PF614-MPAR. A next-generation opioid, PF614-MPAR represents a major….
Micropore Appoints Insung Chroma-Tech Co as Korean Distributor
UK-based particle engineering specialist Micropore Technologies has just announced the appointment of Insung Chroma-Tech Co. as the distributor for its patented membrane technology in the…
